Basilea Pharmaceutica

Results: 17



#Item
1pwc_master_logo_shortform

pwc_master_logo_shortform

Add to Reading List

Source URL: annualreport.basilea.com

Language: English - Date: 2015-03-04 10:40:28
2Microsoft Word - 20150424_FINAL_ECCMID_EN_with links.docx

Microsoft Word - 20150424_FINAL_ECCMID_EN_with links.docx

Add to Reading List

Source URL: www.basilea.com

Language: English
3Microsoft Word - 20150401_Basilea_In-licensing panRAF_EN.docx

Microsoft Word - 20150401_Basilea_In-licensing panRAF_EN.docx

Add to Reading List

Source URL: www.basilea.com

Language: English
4Microsoft Word - 20150429_Basilea_AGM15 Results_EN.docx

Microsoft Word - 20150429_Basilea_AGM15 Results_EN.docx

Add to Reading List

Source URL: www.basilea.com

Language: English
5Microsoft Word - 20150504_Basilea_Start of phase 1 panRAF_EN.docx

Microsoft Word - 20150504_Basilea_Start of phase 1 panRAF_EN.docx

Add to Reading List

Source URL: www.basilea.com

Language: English
6

PDF Document

Add to Reading List

Source URL: reports.standardandpoors.com

Language: English - Date: 2015-02-26 05:00:42
7PRESS RELEASE Swissmedic approves Basilea’s antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia Basel, Switzerland, December 22, 2014 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that the

PRESS RELEASE Swissmedic approves Basilea’s antibiotic Zevtera® (ceftobiprole medocaril) for the treatment of pneumonia Basel, Switzerland, December 22, 2014 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reports that the

Add to Reading List

Source URL: www.basilea.com

Language: English
8PRESS RELEASE Basilea announces that FDA’s Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis Basel, Switzerland, January 22, 2015

PRESS RELEASE Basilea announces that FDA’s Anti-Infective Drugs Advisory Committee recommends approval of isavuconazole for the treatment of invasive aspergillosis and mucormycosis Basel, Switzerland, January 22, 2015

Add to Reading List

Source URL: www.basilea.com

Language: English
9PRESS RELEASE Basilea’s oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study   Results of recently completed clinical phase 1 study presented at ASCO

PRESS RELEASE Basilea’s oncology drug candidate BAL101553 shows first evidence of antitumor activity in phase 1 study  Results of recently completed clinical phase 1 study presented at ASCO

Add to Reading List

Source URL: hbmpartners.com

Language: English - Date: 2014-06-23 09:59:40
10Area News www.baselarea.ch News from the Basel business area  April 2007

Area News www.baselarea.ch News from the Basel business area April 2007

Add to Reading List

Source URL: www.baselarea.ch

Language: English - Date: 2011-03-15 04:41:31